Study guide

8.1 Cystic Fibrosis & Respiratory Support

Board Certified Specialist in Pediatric Nutrition CSP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 CSP Exam Facts, Format & Fees 1.2 Eligibility & Application Process 1.3 Scoring, Test Day Logistics & Study Strategy

2 Pediatric Growth & Development

2.1 Growth Patterns Across Pediatric Age Bands 2.2 Developmental Milestones & Feeding Skill Acquisition

3 Human Milk & Infant Formulas

3.1 Human Milk & Lactation Management 3.2 Milk Handling, Storage, Donor Milk & Fortification 3.3 Infant & Specialized Formulas

4 Age-Appropriate Nutrition & Foods

4.1 Complementary Feeding & Toddler Nutrition 4.2 School-Age & Adolescent Nutrition

5 Prematurity & the NICU Graduate

5.1 Preterm Nutrition in the NICU 5.2 Post-Discharge Nutrition for Preterm Infants

6 Congenital, Developmental & Metabolic Conditions

6.1 Congenital & Neurodevelopmental Conditions 6.2 Inborn Errors of Metabolism

7 GI Disorders & Food Allergy

7.1 Gastrointestinal Disorders: IBD, Celiac, Short Bowel & GERD 7.2 Food Allergy, FPIES & Eosinophilic Esophagitis

8 Body System & Organ Dysfunction

8.1 Cystic Fibrosis & Respiratory Support 8.2 Congenital Heart Disease & Cardiac Conditions 8.3 Chronic Kidney Disease, Dialysis & Transplant

9 Oncology, Endocrine & Weight-Related Care

9.1 Pediatric Oncology & HSCT Nutrition 9.2 Diabetes Management & Ketogenic Diet Therapy 9.3 Pediatric Overweight & Obesity (AAP 2023 Guideline) 9.4 Eating Disorders, ARFID & Pediatric Feeding Disorder

10 Clinical Status & Health History

10.1 Medical Treatment & Medication History 10.2 Nutrition & Supplementation History 10.3 Cultural & Psychosocial Factors 10.4 Activity & Lifestyle History 10.5 Birth, Perinatal & Surgical History

11 Anthropometrics & Growth Assessment

11.1 Anthropometric Measurement Techniques 11.2 Growth Charts & Z-Score Interpretation 11.3 Growth Assessment in Preterm & Special Populations 11.4 Pediatric Malnutrition: AND/ASPEN Consensus Criteria 11.5 Body Composition Assessment in Children

12 Physical Exam, Laboratory Data & Nutrition Diagnosis

12.1 Nutrition-Focused Physical Exam 12.2 Diagnostic & Laboratory Testing 12.3 Micronutrient Status Assessment & Deficiency Workup 12.4 Gastrointestinal Function & Diagnostic Testing 12.5 Nutrition Diagnosis, PES Statements & the NCP

13 Estimation of Nutritional Needs

13.1 Energy Needs Across Age & Clinical State 13.2 Protein & Fluid Requirements 13.3 Micronutrient Needs & Catch-Up Growth 13.4 Estimating Needs in Critical Illness & Special Clinical States

14 Oral Nutrition & Supplementation

14.1 Oral Nutrition & Therapeutic Diet Modification 14.2 Texture Modification & Dysphagia Management 14.3 Vitamin & Mineral Supplementation

15 Enteral Nutrition Support

15.1 Enteral Nutrition: Indications & Access 15.2 Enteral Formula Selection 15.3 Feeding Regimens, Advancement & Complications

16 Parenteral Nutrition Support

16.1 PN Indications & Composition 16.2 PN Initiation, Advancement & Monitoring 16.3 PN Complications & IFALD

17 Care Planning, Coordination & Education

17.1 Monitoring & Evaluation of Nutrition Care 17.2 Interdisciplinary Coordination & Transitions of Care 17.3 Access to Food & Healthcare: Federal Programs 17.4 Education & Counseling for Children & Families 17.5 Documentation, Quality & Outcomes in Pediatric Nutrition Care 17.6 Ethics, Palliative Care & Nutrition Decision-Making

8.1 Cystic Fibrosis & Respiratory Support

Key Takeaways Explain This Topic AI

About 85-90% of people with cystic fibrosis have exocrine pancreatic insufficiency and need pancreatic enzyme replacement therapy with every fat-containing feed.

PERT is dosed at 500-2,500 lipase units/kg/meal (half for snacks), not to exceed 10,000 lipase units/kg/day or 4,000 lipase units/g fat, because higher doses are linked to fibrosing colonopathy.

The Cystic Fibrosis Foundation growth target is BMI-for-age at or above the 50th percentile for ages 2-20, because nutritional status correlates directly with lung function (FEV1).

Screen for cystic fibrosis-related diabetes with an annual oral glucose tolerance test starting at age 10; treat with insulin and never restrict carbohydrate.

In ventilated children, excess carbohydrate raises CO2 production (respiratory quotient approaches 1.0), which can delay ventilator weaning.

Last updated: August 2026

Pathophysiology and Diagnosis of Cystic Fibrosis

Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene on chromosome 7. The defective CFTR protein impairs chloride and bicarbonate transport across epithelial membranes, producing thick, dehydrated secretions in the airways, pancreatic ducts, intestine, and biliary tree. Roughly 85-90% of patients develop exocrine pancreatic insufficiency (PI) , usually in infancy, so fat and protein maldigestion is the default assumption unless proven otherwise.

Newborn screening is universal in the United States: an elevated immunoreactive trypsinogen (IRT) triggers repeat IRT and/or CFTR DNA analysis, with a diagnostic sweat chloride test as the confirmatory step (>=60 mmol/L diagnostic, 30-59 mmol/L intermediate). About 10-20% of newborns with CF present with meconium ileus , which is nearly pathognomonic and signals severe genotype and high risk for early PI.

  • Diagnostic landmark Key point for the RD
  • Newborn screen: IRT +/- DNA panel Refer promptly; nutrition starts at diagnosis, not at symptoms
  • Sweat chloride >=60 mmol/L Confirms CF; also explains high salt losses
  • Meconium ileus at birth Assume PI; start PERT once feeds begin
  • Fecal elastase-1 <200 ug/g Confirms pancreatic insufficiency
  • Energy and Macronutrient Needs

Classic CF guidelines recommended energy intakes of 110-200% of age-related norms to overcome maldigestion, chronic infection, and the work of breathing; current practice individualizes the prescription to weight gain, growth velocity, and lung status, and energy needs often fall once a patient responds to a CFTR modulator. The diet is deliberately high in fat (35-40% of kcal) with no fat restriction — fat is the most energy-dense way to close the calorie gap. The Cystic Fibrosis Foundation (CFF) growth target is BMI-for-age at or above the 50th percentile for ages 2-20 (and weight-for-length >=50th percentile under age 2), because better nutritional status is strongly associated with better forced expiratory volume in 1 second (FEV1) .

Pancreatic Enzyme Replacement Therapy (PERT)

Pancreatic enzyme replacement therapy replaces lipase, protease, and amylase. Standard starting doses are 500-2,500 lipase units/kg per meal and about half that dose per snack , titrated to symptoms and growth. Do not exceed 10,000 lipase units/kg/day or 4,000 lipase units/g of dietary fat , because very high doses are associated with fibrosing colonopathy . Products are enteric-coated microspheres that must be given with all fat-containing feeds , including breast milk and infant formula — capsules are opened and the beads are mixed into an acidic soft food (such as applesauce) for infants, without crushing or chewing, which destroys the coating.

Signs of under-dosing: steatorrhea (oily, foul, floating stools), gas, abdominal distension and pain, and poor weight gain or growth faltering.

Signs of over-dosing: constipation and hard stools; chronic overdose raises the risk of distal intestinal obstruction syndrome (DIOS) and, at extreme doses, fibrosing colonopathy.